Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Research output: Contribution to journalArticle

Abstract

Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial. Design and Methods Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years. Results Baseline myocardial T2* was severe (>5 to

Original languageEnglish
Pages (from-to)48-54
Number of pages7
JournalHaematologica
Volume96
Issue number1
DOIs
Publication statusPublished - Jan 2011

Keywords

  • β-thalassemia major
  • Cardiac iron overload
  • Deferasirox
  • Iron chelation
  • Myocardial T2*

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload'. Together they form a unique fingerprint.

  • Cite this

    Pennell, D. J., Porter, J. B., Cappellini, M. D., Chan, L. L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, C. K., Viprakasit, V., Elalfy, M. S., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., & Taher, A. (2011). Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica, 96(1), 48-54. https://doi.org/10.3324/haematol.2010.031468